by Jason | Jan 21, 2021 | Industry News
Expert perspectives in ulcerative colitis: An interview with Dr Peter Irving Ulcerative colitis (UC) is a debilitating inflammatory bowel disease (IBD) affecting approximately 1 in 250 people in the UK.1 Galapagos UK Medical Advisor, Claire Hamilton spoke with Dr...
by Jason | Jan 21, 2021 | Industry News
We are Galapagos UK: The unknown is our comfort zone. Who we are We are Galapagos, a pioneering biotechnology company, founded in Belgium in 1999 by our CEO Onno van de Stolpe, focused on discovering and developing innovative medicines to improve peoples’ lives. We...
by Jason | Jan 21, 2021 | Industry News
Looking to the future in inflammatory bowel disease (IBD) care: Perspectives from Professor Charlie Lees Professor Charlie Lees is a Consultant Gastroenterologist in the Edinburgh IBD Unit, and Professor of Gastroenterology at the University of Edinburgh. He will be...
by Jason | Jan 11, 2021 | Industry News
Switching from intravenous to subcutaneous infliximab biosimilar (Remsima®) in adult patients with inflammatory bowel disease: experience at an NHS trust Dr. Ajay Verma, consultant gastroenterologist and physician, and Anusha Patel, regional homecare lead pharmacist...
by Jason | Jan 11, 2021 | Industry News
As we all know COVID-19 has impacted everyone’s lives this year and changed the way in which we all now work and interact with each other; for us this meant that face to face training was no longer possible. With this realisation our Professional Education team...
Recent Comments